mesoblast
the regenerative medicine company

asx announcement

For personal use only

Mesoblast Included in S&P/ASX 200 Index

Melbourne, Australia; 18 April 2011: Standard and Poor's (S&P) Indices has announced that regenerative medicine company Mesoblast Limited (ASX:MSB) will be included in the S&P/ASX 200 Index, effective after the close of business on Wednesday 27 April, 2011.

"Inclusion in the S&P/ASX 200 index is a major achievement for Mesoblast," said Chief Executive Professor Silviu Itescu. "This important milestone serves to further underscore the company's strong financial performance and global leadership in the field of regenerative medicine."

About S&P/ASX 200
The S&P/ASX 200 is recognized as the primary investable benchmark in Australia. The index covers approximately 78% of Australian equity market capitalization. Index constituents are drawn from eligible companies listed on the Australian Securities Exchange. This index is designed to address investment managers' needs to benchmark against a portfolio characterized by sufficient size and liquidity.

About S&P Indices
S&P Indices, the world's leading index provider, maintains a wide variety of investable and benchmark indices to meet an array of investor needs. Over $1.25 trillion is directly indexed to Standard & Poor's family of indices.

About Mesoblast Limited
Mesoblast Limited (ASX: MSB; OTC ADR:MBLTY) is a world leader in the development, manufacture, and commercialization of biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights to a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). More information - www.mesoblast.com

For further information, please contact:
Julie Meldrum
Corporate Communications Director
T: + 61 (0) 3 9639 6036
E: julie.meldrum@mesoblast.com